# Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

> **NCT04042051** · PHASE1 · TERMINATED · sponsor: **Cancer Trials Ireland** · enrollment: 2 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Unresectable Breast Cancer

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT04042051
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-12
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Accrual rate to date was too low to finish the trial in a reasonable timeframe
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042051, "Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04042051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*